RBC Capital has initiated coverage on Bicycle Therapeutics PLC (BCYC), highlighting the potential of its lead program, Zelenectide pevedotin (zele), in the oncology market. The analyst believes that Zele’s improved safety profile compared to Padcev, a competing drug for metastatic urothelial cancer (mUC), could lead to greater antitumor durability and a substantial market share. Furthermore, the analyst sees potential for Zele in other solid tumors, such as triple-negative breast cancer and non-small cell lung cancer, with an estimated peak global sales of $2 billion in 2033.
